CatalystMarker
← board

MENS

distress 5/10 · elevated risk
$2.640%today-96% from 52w high
jyongbio.com27 employeesFounded 2002New Taipei City, TaiwanBiotechnology
Revenue
pre-revenue
Liquidity
$1M
Runway
0.4 yrs
Shares 1y

Price & events

-16.5% over 6M
$1.46$2.31$3.16Jan 26Apr 26Jul 261.3M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+14.8%
1W
+61.0%
1M
+16.3%
3M
-12.9%
6M
-76.3%
1Y
2Y
5Y
-73.9%
All

Overview

Market Cap
$200.71M
Enterprise Value
$201.66M
Volume
7.84K
52 Week Range
$1.46 – $65.62
Total Shares
76.03M
Float Shares
26.94M
Short %
0.51%
% Held by Insiders
62.20%
% Held by Institutions
0.71%
RVOL
0.06x

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 76,027,667 · 0 offerings/1y · 0 PIPEs
  • 2025-06-18424B4offering
  • 2025-06-16EFFECTshelf_effective
  • 2025-03-31EFFECTshelf_effective
  • 2025-03-27FWPoffering
  • 2025-03-27FWPoffering
  • 2025-03-11F-1/Ashelf_registration
  • 2025-02-18FWPoffering
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.